C4 Therapeutics (CCCC) Stock Forecast & Price Target

Compare

632 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CCCC Analyst Ratings

Strong Buy

3 Buy

0 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CCCC Stock 12 Month Forecast

Average Price Target

$6.00

▲(180.37% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for C4 Therapeutics in the last 3 months. The average price target is $6.00 with a high forecast of $7.00 and a low forecast of $5.00. The average price target represents a 180.37% change from the last price of $2.14.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","2":"$2","4":"$4","6":"$6","8":"$8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2,4,6,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.91,2.3015384615384615,2.693076923076923,3.0846153846153843,3.4761538461538457,3.867692307692307,4.259230769230769,4.650769230769231,5.042307692307692,5.4338461538461535,5.825384615384615,6.216923076923076,6.608461538461539,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.91,2.2246153846153844,2.539230769230769,2.853846153846154,3.168461538461538,3.483076923076923,3.7976923076923077,4.112307692307692,4.426923076923077,4.741538461538462,5.056153846153847,5.3707692307692305,5.685384615384615,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.91,2.147692307692308,2.3853846153846154,2.623076923076923,2.8607692307692307,3.0984615384615384,3.336153846153846,3.5738461538461537,3.8115384615384613,4.049230769230769,4.286923076923077,4.524615384615385,4.762307692307692,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.71,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.51,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.15,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.61,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.54,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$7.00

Average Price Target$6.00

Lowest Price Target$5.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

Buy

227.10%

Upside

Reiterated

12/18/25

Evercore ISI Remains a Buy on C4 Therapeutics (CCCC)

Etzer Darout

Barclays

$10→$5

Buy

133.64%

Upside

Reiterated

12/17/25

Barclays Keeps Their Buy Rating on C4 Therapeutics (CCCC)

Tyler Van Buren

TD Cowen

Buy

―

Initiated

12/02/25

C4 Therapeutics' Innovative Drug Development and Promising Clinical Trials Support Buy Rating

Derek Archila

Wells Fargo

$5→$10

Buy

367.29%

Upside

Reiterated

09/23/25

C4 Therapeutics price target raised to $10 from $5 at Wells FargoC4 Therapeutics price target raised to $10 from $5 at Wells Fargo

Terence Flynn

Morgan Stanley

Hold

―

Reiterated

09/21/25

C4 Therapeutics: Balancing Promise and Competition in the Multiple Myeloma Market

Sudan Loganathan

Stephens

$3→$6

Buy

180.37%

Upside

Upgraded

09/15/25

C4 Therapeutics: Promising Growth and Competitive Edge with TORPEDO Platform and Strategic Partnerships

Bradley Canino

Guggenheim

Buy

273.83%

Upside

Initiated

09/03/25

C4 Therapeutics initiated with a Buy at GuggenheimC4 Therapeutics initiated with a Buy at Guggenheim

Unknown Analyst

UBS

Not Ranked

UBS

$4→$3.5

Hold

63.55%

Upside

Reiterated

03/03/25

C4 Therapeutics (CCCC) PT Lowered to $3.50 at UBSUBS analyst Colin Bristow lowered the price target on C4 Therapeutics (NASDAQ: CCCC) to $3.50 (from $4.00) while maintaining a Neutral rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

Buy

227.10%

Upside

Reiterated

12/18/25

Evercore ISI Remains a Buy on C4 Therapeutics (CCCC)

Etzer Darout

Barclays

$10→$5

Buy

133.64%

Upside

Reiterated

12/17/25

Barclays Keeps Their Buy Rating on C4 Therapeutics (CCCC)

Tyler Van Buren

TD Cowen

Buy

―

Initiated

12/02/25

C4 Therapeutics' Innovative Drug Development and Promising Clinical Trials Support Buy Rating

Derek Archila

Wells Fargo

$5→$10

Buy

367.29%

Upside

Reiterated

09/23/25

C4 Therapeutics price target raised to $10 from $5 at Wells FargoC4 Therapeutics price target raised to $10 from $5 at Wells Fargo

Terence Flynn

Morgan Stanley

Hold

―

Reiterated

09/21/25

C4 Therapeutics: Balancing Promise and Competition in the Multiple Myeloma Market

Sudan Loganathan

Stephens

$3→$6

Buy

180.37%

Upside

Upgraded

09/15/25

C4 Therapeutics: Promising Growth and Competitive Edge with TORPEDO Platform and Strategic Partnerships

Bradley Canino

Guggenheim

Buy

273.83%

Upside

Initiated

09/03/25

C4 Therapeutics initiated with a Buy at GuggenheimC4 Therapeutics initiated with a Buy at Guggenheim

Unknown Analyst

UBS

Not Ranked

UBS

$4→$3.5

Hold

63.55%

Upside

Reiterated

03/03/25

C4 Therapeutics (CCCC) PT Lowered to $3.50 at UBSUBS analyst Colin Bristow lowered the price target on C4 Therapeutics (NASDAQ: CCCC) to $3.50 (from $4.00) while maintaining a Neutral rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering C4 Therapeutics

3 Months

xxx

Success Rate

7/19 ratings generated profit

Average Return

+18.72%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 36.84% of your transactions generating a profit, with an average return of +18.72% per trade.

1 Year

Etzer DaroutBarclays

Success Rate

5/19 ratings generated profit

Average Return

-13.71%

reiterated a buy rating last month

Copying Etzer Darout's trades and holding each position for 1 Year would result in 26.32% of your transactions generating a profit, with an average return of -13.71% per trade.

2 Years

xxx

Success Rate

3/19 ratings generated profit

Average Return

-32.73%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 15.79% of your transactions generating a profit, with an average return of -32.73% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CCCC Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CCCC has received 4 Buy Ratings, 16 Hold Ratings, and 1 Sell Ratings. CCCC average Analyst price target in the past 3 months is 6.00.

Each month's total comprises the sum of three months' worth of ratings.

CCCC Financial Forecast

CCCC Earnings Forecast

Next quarter’s earnings estimate for CCCC is -$0.29 with a range of -$0.45 to -$0.02. The previous quarter’s EPS was -$0.44. CCCC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year CCCC has Performed in-line its overall industry.

CCCC Sales Forecast

Next quarter’s sales forecast for CCCC is $5.39M with a range of $69.00K to $10.00M. The previous quarter’s sales results were $11.23M. CCCC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year CCCC has Performed in-line its overall industry.

CCCC Stock Forecast FAQ

What is CCCC’s average 12-month price target, according to analysts?

Based on analyst ratings, C4 Therapeutics’s 12-month average price target is 6.00.

What is CCCC’s upside potential, based on the analysts’ average price target?

C4 Therapeutics has 180.37% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CCCC a Buy, Sell or Hold?

C4 Therapeutics has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is C4 Therapeutics’s price target?

The average price target for C4 Therapeutics is 6.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $7.00 ,the lowest forecast is $5.00. The average price target represents 180.37% Increase from the current price of $2.14.

What do analysts say about C4 Therapeutics?

C4 Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of CCCC?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

C4 Therapeutics (CCCC) Stock Forecast & Price Target

CCCC Analyst Ratings

CCCC Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering C4 Therapeutics

CCCC Analyst Recommendation Trends

CCCC Financial Forecast

CCCC Earnings Forecast

CCCC Sales Forecast

CCCC Stock Forecast FAQ

Detailed List of Analyst Forecasts